drugIndia
Cart
Glimixia-VM1 Tablet ER

Glimixia-VM1 Tablet ER

Glimepiride (1mg) + Voglibose (0.2mg) + Metformin (500mg)

Wings Biotech Ltd
Anti-Vomiting
100.00125.0020% OFF
In Stock
1
Safe & Secure
Easy Returns
24/7 Support
Delivery
drugIndia verified
Save 68%
Best Alternative100% Match

Glimison-VM 1 Tablet SR

Unison Pharmaceuticals Pvt Ltd

Voglibose 0.2mg
Glimison-VM 1 Tablet SR

Pack Size

1 units

Price

31.6020% off
Glimison-VM 1 Tablet SR is 100% same as Glimixia-VM1 Tablet ER
Better ValueSame QualitySame Effectiveness

Save ₹68

that's 68% off!

composition
  1. Voglibose 0.2mg
  2. Glimepiride 1mg
  3. Metformin 500mg
Buy Now
100.0020% OFF
125.00

About This Medicine

Product description & overview

Glimixia-VM1 Tablet ER: A Comprehensive Once-Daily Treatment

Glimixia-VM1 is a once-daily extended-release tablet formulated to effectively manage Type 2 Diabetes Mellitus (T2DM). This combination therapy combines three key ingredients for optimal blood sugar control:

* Glimepiride (1mg): A sulfonylurea that stimulates insulin release from the pancreas, lowering blood glucose levels.
* Metformin (500mg): A first-line oral antidiabetic drug that reduces hepatic glucose production and enhances peripheral glucose uptake.
* Voglibose (0.2mg): An alpha-glucosidase inhibitor that prevents the absorption of glucose from the small intestine, contributing to further blood sugar control.

Glimixia-VM1 offers convenience with a single daily dose, simplifying medication adherence and potentially enhancing patient experience.

Please note: Consult your physician before starting any new treatment regimen. This information is for educational purposes only and does not substitute medical advice.

Active composition

Glimepiride 1 mg

+2 more active ingredients

About Glimepiride

Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.

How It Works

Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.

Medicine Strength
1 mg

All Active Ingredients

Glimepiride1 mg
Voglibose0.2 mg
Metformin500 mg

Voglibose

Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.

Metformin

Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.

Safety Advice

Important precautions

Side Effect Occurrence

Based on clinical trials and patient reports.

Overall Tolerance

Most patients tolerate well

Only 2.3% reported effects

Common Side Effects

Headache8%
Nausea5%
Dizziness3%
Fatigue2%
Rash1%
Higher
Lower

Safety Advice

Alcohol

It is unsafe to consume alcohol with Glimixia-VM1 Tablet ER.

High Risk

Pregnancy

Glimixia-VM1 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Medical Advice

Driving

Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.

Exercise Caution

Liver

Glimixia-VM1 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Glimixia-VM1 Tablet ER may be needed. Please consult your doctor. Glimixia-VM1 Tablet ER is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.

Regular Checkup

Breastfeeding

Glimixia-VM1 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Consult Doctor

Kidney

Glimixia-VM1 Tablet ER is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Glimixia-VM1 Tablet ER is, however, not recommended in patients with severe kidney disease.

Regular Checkup

Customer Reviews

0 reviews for Glimixia-VM1 Tablet ER

Products matching your search